Last reviewed · How we verify
Rebamipide and Omeprazole
Rebamipide and Omeprazole is a Mucoprotective agent + Proton pump inhibitor combination Small molecule drug developed by Otsuka Pakistan Limited. It is currently in Phase 3 development for Gastric ulcer disease, Gastroesophageal reflux disease (GERD), Gastric mucosal protection in peptic ulcer disease. Also known as: Mucosta, Omeprazole.
Rebamipide protects and promotes gastric mucosa healing while omeprazole reduces gastric acid secretion by inhibiting the proton pump.
Rebamipide protects and promotes gastric mucosa healing while omeprazole reduces gastric acid secretion by inhibiting the proton pump. Used for Gastric ulcer disease, Gastroesophageal reflux disease (GERD), Gastric mucosal protection in peptic ulcer disease.
At a glance
| Generic name | Rebamipide and Omeprazole |
|---|---|
| Also known as | Mucosta, Omeprazole |
| Sponsor | Otsuka Pakistan Limited |
| Drug class | Mucoprotective agent + Proton pump inhibitor combination |
| Target | Rebamipide: gastric mucosa protective pathways; Omeprazole: H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Rebamipide is a mucoprotective agent that enhances gastric mucus secretion, increases bicarbonate production, and promotes mucosal blood flow to protect the stomach lining. Omeprazole is a proton pump inhibitor that suppresses gastric acid production by blocking H+/K+-ATPase in parietal cells. Together, this combination provides both acid reduction and direct mucosal protection for enhanced gastroprotection.
Approved indications
- Gastric ulcer disease
- Gastroesophageal reflux disease (GERD)
- Gastric mucosal protection in peptic ulcer disease
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Dizziness
Key clinical trials
- Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia (PHASE4)
- Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy (PHASE4)
- Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation (PHASE3)
- Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rebamipide and Omeprazole CI brief — competitive landscape report
- Rebamipide and Omeprazole updates RSS · CI watch RSS
- Otsuka Pakistan Limited portfolio CI
Frequently asked questions about Rebamipide and Omeprazole
What is Rebamipide and Omeprazole?
How does Rebamipide and Omeprazole work?
What is Rebamipide and Omeprazole used for?
Who makes Rebamipide and Omeprazole?
Is Rebamipide and Omeprazole also known as anything else?
What drug class is Rebamipide and Omeprazole in?
What development phase is Rebamipide and Omeprazole in?
What are the side effects of Rebamipide and Omeprazole?
What does Rebamipide and Omeprazole target?
Related
- Drug class: All Mucoprotective agent + Proton pump inhibitor combination drugs
- Target: All drugs targeting Rebamipide: gastric mucosa protective pathways; Omeprazole: H+/K+-ATPase (proton pump)
- Manufacturer: Otsuka Pakistan Limited — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastric ulcer disease
- Indication: Drugs for Gastroesophageal reflux disease (GERD)
- Indication: Drugs for Gastric mucosal protection in peptic ulcer disease
- Also known as: Mucosta, Omeprazole
- Compare: Rebamipide and Omeprazole vs similar drugs
- Pricing: Rebamipide and Omeprazole cost, discount & access